According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “
VBLT has been the topic of a number of other research reports. Piper Jaffray Companies reaffirmed an overweight rating and set a $11.00 target price on shares of Vascular Biogenics in a research note on Tuesday, February 21st. Chardan Capital set a $20.00 target price on shares of Vascular Biogenics and gave the stock a buy rating in a research note on Tuesday, November 29th. Finally, Roth Capital reiterated a buy rating and set a $17.00 price target on shares of Vascular Biogenics in a report on Thursday, December 1st. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $12.90.
Vascular Biogenics (NASDAQ:VBLT) traded up 4.81% on Friday, reaching $5.45. The company’s stock had a trading volume of 238,718 shares. The stock’s 50 day moving average is $5.58 and its 200-day moving average is $5.23. The firm’s market capitalization is $146.62 million. Vascular Biogenics has a 52 week low of $3.03 and a 52 week high of $7.58.
Vascular Biogenics (NASDAQ:VBLT) last posted its earnings results on Monday, March 27th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. Analysts predict that Vascular Biogenics will post ($0.66) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.com-unik.info/2017/04/21/vascular-biogenics-ltd-vblt-cut-to-sell-at-zacks-investment-research-updated-updated.html.
An institutional investor recently raised its position in Vascular Biogenics stock. Menta Capital LLC raised its position in Vascular Biogenics Ltd (NASDAQ:VBLT) by 46.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 115,735 shares of the biopharmaceutical company’s stock after buying an additional 36,482 shares during the period. Menta Capital LLC owned about 0.43% of Vascular Biogenics worth $561,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 14.95% of the company’s stock.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Vascular Biogenics Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vascular Biogenics Ltd and related companies.